- Published on
Medicine – Disseminated Intravascular Coagulation (DIC)
Disseminated intravascular coagulation (DIC) is a life-threatening, acquired syndrome characterised by widespread activation of coagulation, formation of microvascular thrombi, consumption of platelets and coagulation factors, and potentially severe bleeding and organ dysfunction.
DIC is also known as consumption coagulopathy.
The characteristic feature of DIC is the simultaneous occurrence of thrombosis and bleeding. Microvascular fibrin deposition contributes to organ dysfunction, while consumption of platelets and coagulation factors contributes to haemorrhage.
1. Pathophysiology of DIC
DIC is triggered by excessive activation of the coagulation system, commonly through tissue factor exposure and inflammatory pathways.
- Procoagulant activation: Tissue factor and other procoagulant pathways activate coagulation.
- Excessive thrombin generation: Widespread coagulation activation occurs.
- Fibrin deposition: Fibrin-rich microthrombi form within small blood vessels.
- Consumption: Platelets and coagulation factors are consumed.
- Fibrin turnover: Fibrinolysis produces fibrin degradation products and D-dimer.
- Clinical consequences: Bleeding, microvascular thrombosis and organ dysfunction develop.
Illustration: Pathophysiology Flowchart
2. Laboratory Findings in DIC
| Investigation | Typical Finding |
|---|---|
| Prothrombin time (PT) | Prolonged |
| Activated partial thromboplastin time (aPTT) | Prolonged; may be normal early |
| Thrombin time (TT) | Normal or prolonged |
| Bleeding time (BT) | May be prolonged; rarely used clinically |
| Platelet count | Decreased (thrombocytopenia) |
| Fibrinogen | Reduced or falling; may initially be normal or increased |
| Fibrin degradation products (FDP) | Increased |
| D-dimer | Increased, often markedly |
| Peripheral blood film | May show schistocytes (fragmented erythrocytes) |
Explanation of Laboratory Abnormalities
- Prolonged PT and aPTT: Consumption of coagulation factors.
- Thrombocytopenia: Platelet activation and consumption within microthrombi.
- Elevated D-dimer: Breakdown of cross-linked fibrin.
- Reduced fibrinogen: Consumption during widespread fibrin formation.
- Schistocytes: Mechanical fragmentation of erythrocytes within the microcirculation.
3. Causes of DIC
A. Obstetric Causes
| Cause | Mechanism |
|---|---|
| Placental abruption (retroplacental haemorrhage) | Release of tissue factor from damaged placental tissue |
| Retained dead fetus | May trigger coagulation activation, particularly with prolonged retention |
| Amniotic fluid embolism | Sudden inflammatory and coagulation activation |
| Severe pre-eclampsia / HELLP syndrome | Endothelial injury and coagulation activation |
| Septic abortion | Sepsis-associated coagulation activation |
| Severe postpartum haemorrhage | May be associated with DIC in severe obstetric complications |
B. Non-Obstetric Causes
| Cause | Clinical Significance |
|---|---|
| Sepsis / septicaemia | Major cause, particularly severe bacterial sepsis |
| Major trauma / crush injury | Tissue injury and systemic inflammatory activation |
| Malignancy | Particularly acute promyelocytic leukaemia and certain adenocarcinomas |
| Severe liver disease | May coexist with DIC or produce similar laboratory abnormalities |
| Acute haemolytic transfusion reaction | Systemic coagulation activation |
| Fat embolism syndrome | May be associated with coagulation activation and DIC |
| Severe pancreatitis | Inflammation and tissue injury |
| Major burns | Tissue damage and systemic inflammation |
4. Clinical Features of DIC
DIC may present predominantly with bleeding, thrombosis or organ dysfunction.
A. Bleeding Manifestations
- Oozing from venepuncture sites or surgical wounds.
- Petechiae, purpura and ecchymoses.
- Epistaxis and gingival bleeding.
- Gastrointestinal bleeding.
- Haematuria.
- Severe postpartum haemorrhage.
B. Thrombotic and Organ Manifestations
- Acute kidney injury.
- Respiratory failure.
- Altered mental status.
- Digital ischaemia.
- Skin necrosis or purpura fulminans.
- Multiorgan dysfunction.
5. Diagnosis of DIC
DIC is diagnosed using the clinical context together with laboratory abnormalities. No single investigation confirms or excludes DIC.
The International Society on Thrombosis and Haemostasis (ISTH) overt DIC score is commonly used in patients with an underlying condition associated with DIC.
ISTH Overt DIC Scoring System
| Parameter | Score |
|---|---|
| Platelets ≥100 × 109/L | 0 |
| Platelets 50–99 × 109/L | 1 |
| Platelets <50 × 109/L | 2 |
| No increase in fibrin-related markers | 0 |
| Moderate increase in fibrin-related markers | 2 |
| Strong increase in fibrin-related markers | 3 |
| PT prolongation <3 seconds | 0 |
| PT prolongation 3–6 seconds | 1 |
| PT prolongation ≥6 seconds | 2 |
| Fibrinogen ≥1 g/L | 0 |
| Fibrinogen <1 g/L | 1 |
A total score of 5 or more is compatible with overt DIC in the appropriate clinical setting.
A score below 5 does not exclude evolving DIC; repeat assessment may be required. The scoring system should only be applied when an underlying disorder associated with DIC is present.
6. Treatment of DIC
The fundamental principle is to treat the underlying cause while providing appropriate supportive care.
A. Treat the Underlying Cause
- Sepsis: Prompt antimicrobial therapy and source control.
- Obstetric DIC: Urgent treatment of the obstetric emergency.
- Trauma: Haemorrhage control and resuscitation.
- Acute promyelocytic leukaemia: Urgent specialist-directed treatment, including all-trans retinoic acid (ATRA) when suspected.
B. Blood Component Replacement
| Blood Component | Indication |
|---|---|
| Packed red blood cells | Significant bleeding or anaemia requiring transfusion |
| Platelets | Active bleeding with thrombocytopenia, or preparation for high-risk procedures |
| Fresh-frozen plasma (FFP) | Active bleeding or invasive procedures with significant coagulation factor deficiency |
| Cryoprecipitate / fibrinogen concentrate | Bleeding with low fibrinogen |
In actively bleeding patients, clinicians commonly aim for a platelet count of at least 50 × 109/L and adequate fibrinogen replacement, often targeting at least 1.5 g/L in major haemorrhage, according to the clinical situation and local protocols.
C. Anticoagulation
Heparin is not routinely administered to every patient with DIC.
Therapeutic anticoagulation may be considered when thrombosis predominates, such as documented venous thromboembolism or selected cases of digital ischaemia, after specialist assessment of bleeding risk.
Patients with DIC who are not actively bleeding may also require standard VTE prophylaxis when appropriate.
D. Supportive Management
- Haemodynamic resuscitation.
- Oxygenation and organ support.
- Serial monitoring of platelet count, PT, aPTT, fibrinogen and D-dimer.
- Management of shock, renal failure and other complications.
7. Treatment Flowchart
8. DIC Versus Thrombotic Thrombocytopenic Purpura (TTP)
| Feature | DIC | TTP |
|---|---|---|
| Primary mechanism | Systemic coagulation activation | Severe ADAMTS13 deficiency with platelet-rich microthrombi |
| Platelet count | Decreased | Decreased |
| Schistocytes | May be present | Common |
| PT / aPTT | Often prolonged | Usually normal |
| D-dimer | Often markedly increased | Variable |
| Fibrinogen | May be decreased | Usually normal |
| Main treatment | Treat cause and support coagulation | Urgent plasma exchange and specialist therapy |
9. High-Yield Examination Summary
| Aspect | Important Point |
|---|---|
| Definition | Systemic coagulation activation with consumption of platelets and factors |
| Pathophysiology | Thrombin generation, fibrin deposition, consumption and variable fibrinolysis |
| Laboratory findings | Prolonged PT/aPTT, thrombocytopenia, elevated D-dimer, falling fibrinogen |
| Blood film | May show schistocytes |
| Major causes | Sepsis, trauma, malignancy, obstetric emergencies |
| Diagnosis | Clinical context, serial laboratory tests and ISTH score |
| Treatment | Treat underlying cause, blood components when indicated, supportive care |
| Heparin | Reserved for selected thrombotic presentations |
10. Key Examination Pearls
- DIC is a consumption coagulopathy involving both microvascular thrombosis and bleeding.
- Tissue factor-driven coagulation activation is an important mechanism.
- The classical laboratory pattern is prolonged PT/aPTT, thrombocytopenia, elevated D-dimer and reduced fibrinogen.
- Schistocytes may appear due to microangiopathic haemolysis.
- Sepsis is a major cause of DIC.
- Acute promyelocytic leukaemia is a classic malignancy-associated cause.
- Placental abruption and amniotic fluid embolism are important obstetric triggers.
- The ISTH overt DIC score is compatible with overt DIC when the total is at least 5 in the appropriate clinical setting.
- Treatment focuses on the underlying cause and appropriate blood component support.
- Heparin is reserved for selected circumstances rather than routine treatment of all DIC.
DIC produces simultaneous systemic coagulation activation, consumption of platelets and coagulation factors, fibrin deposition and variable fibrinolysis. This explains the characteristic combination of thrombosis, bleeding and organ dysfunction.
DIC is a medical emergency requiring urgent treatment of the underlying cause and careful management of bleeding, thrombosis and organ dysfunction. Transfusion and anticoagulation decisions must be individualised according to clinical circumstances and local protocols.
Kembara Xtra – Medicine Revision Notes